a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are the results coming out better than planned?
That is the question....IT IS EITHER, ORR?!
"...The primary study objective of this multi-center, open label Phase I dose escalation study is to characterize the safety and tolerability of CLR 131 administered as a single dose, 30-minute infusion in patients with relapsed or refractory multiple myeloma. Secondary study objectives include establishment of a recommended single dose for Phase II, both with and without dexamethasone, as well as an assessment of therapeutic activity..."
They remain coy and clinical...let the scientific cat out of the box, pleeeese!,
Will be watching for Pre-market trades
...In the morning.
My account is authorized for pre-market trading.
Rational exuberance here?
Well I sure am feeling good about CLRB lately!
Last hour buying makes me wonder if something good is in store for us in the first hour of trading tomorrow.
News travels fast these days!
Either that was a quick flipper correction in the young uptrend,
or a warning that we are topping the trend.
SHOULD WE BUY THE DIP?
You got me there. Flippers paradise...investors' terrors?
Time will tell...
HAPPY HOUR ENDED EARLY: $2.50's range retracing
Now that is healthier...nothing goes straight up...usually...lol
Actually, I bet this morning's presentation was stock and uneventful:
NEW YORK, NY / ACCESSWIRE / February 9, 2017 / Cellectar Biosciences (CLRB), an oncology-focused, clinical stage biotechnology company, announces today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 8:30 AM EST in the Tribeca Room of Convene Conference Center, 730 Third Avenue in New York City.
We are trading the $2.60's range, folks, AMAZING
WHAT's UP? Bid 2.63 Ask: 2.65
"...Cellectar and strategy
Cellectar is deep into the process of providing proof of concept for its PDC platform, continuing its CLR 131 franchise and advancing early-stage development chemotherapeutic conjugates so that when applied through the PDC process, they can achieve significantly higher therapeutic benefits for patients.
Unlocking the power exuding from the platform is key because once it is established as a breakthrough technology, its use in delivering a targeted therapeutic dose of treatment will be applicable through a wide range of cancer-targeting therapies. This is the "protein" within the company, and like all good high-protein meals, it could make Cellectar extremely strong.
The basis for the PDC delivery platform is to deliver a phospholipid ether cancer-targeting vehicle, exploiting selective cancer and cancer stem cells, allowing for the uptake and prolonged retention in malignant cells. By being able to attach to a diverse set of oncologic payloads, the PDC platform may prove to have the ability to treat a broad range of cancer indications.
While I want you to take my word as to the platform's merit, it is worth it to acknowledge two peer-reviewed publications that offer extensive research and scientific validation of PDC. In an article published by Nature Reviews Clinical Oncology titled "Beyond The Margins: Real Time Detection of Cancer Using Targeted Fluorophores," the review team evaluated the current use of fluorescent molecules in cancer diagnostics as well as the fluorescence-guided surgical resection of tumors. The report focused on the need for the use of targeted delivery of molecules to malignant tissue. The peer-reviewed data in both reports was consistent in several conclusions, but one clearly stands out to benefit Cellectar: both journals provided insight, review and validation of the unique potential and varied utility of its PDC platform. With this validation comes the increased likelihood of partnership and licensing opportunities as the company continues to mature the pipeline...".
Make that up 3 cents in Pre-Market!
A few weeks ago, it would open up big and then lose most but not all it's gains over the next 5+ hours.
Now, it has been opening up nicely, but keeps going up nicely or at least holds all its first hour gains.
= ACCUMULATION IN SIZE!
Opened at $2.59 and settling back in first 10 minutes of trading. GLTAL
Who runs Cormorant & over 4% CLRB?
Ms. Bihua Chen out of Penn's Wharton school of business:
http://www.bloomberg.com/research/stocks/private/person.asp?personId=214564565&privcapId=241867851
See News Alert above today:
http://ih.advfn.com/p.php?pid=nmona&article=73860950&symbol=CLRB
CLRB worth a chart after yours 1/23/17
Right?
Claytrader due: Good to see strong demand,
Clay Trader should be here soon with his charting!
Here is his last video chart analysis:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128110297
So far so good: 1st target $4
By 4-1-17. Then retrace before $7.50 base on T/A in July. OCICBW
Amended Ownership = our buyer???
http://archive.fast-edgar.com//20170214/ATZM9222S222B2Z2222M2MZZCQVLZ2HRB292/
Price holding at $2.32- I feel Good!
https://finance.yahoo.com/news/cellectar-biosciences-pdc-delivery-platform-205418085.html
PLEASE BE FOR REAL FOR MORE REASONS THAN MONEY!
Sunofwolf: yup- that gives me confidence
This is not a pump & dump stock. That does not make it good science and medicine, but it helps to have a honest and lawful foundation with management. It is hard to weigh turnover in management of an early development stage company, but it is "looking good so far". FAMEOUS LAST WORDS!
LET'S SEE WHERE THIS PUPPY CLOSES TODAY. THAT WILL TELL ME WHO IS IN CHARGE, THE FLIPPERS OR THE LONGER TERM INVESTORS WHO KNOW SOMETHING WE DO NOT!
$2.32- Thompson Reuters i/b/e/s issued STRONG BUY
...ON CLRB. WONDER WHAT IS GOING ON TODAY. MANIPULATION OF SHARE PRICE OR INSIDE INFORMATION LEAKING OUT ABOUT CLRB SCIENCE, BUY-OUT INTEREST OR PARTNERSHIP ON FATTY ACID PLATFORM FOR OTHER'S PAYLOADS?
STAY TUNED AND HAVE AN EXIT PLAN IN ADVANCE FOR SURVIVAL. MS. MARKET IS A BITCH!
SEC regulations prohibit private material information
from being privately released to an investor who calls the company. It would lead to illegal insider trading in violation, inter alia, of Section 10-b-5 of the old Securities Act still in effect.
Perhaps, just perhaps, the price indicator for this stock is the best inside information there is. And this morning the price over $2.30 per share means we are on up trend for now. Why fight it? The trend is your friend- until it changes and "unfriends" you. LOL
We will know later this year if CLRB is AT LEAST A 10 BAGGER from here or a scam heading to PENNYLAND
Until then, I PREFER TO HEAR BOTH SIDES OF THE ARGUMENT ONLY WITH VERIFIABLE FACTS- NOT EMPTY TALES OF BLISS OR TERROR. BASELESS FEAR AND GREED ARE TOOLS OF EVIL MEANT TO DECIEVE NOT REVEAL THE TRUTH.
This is why I appreciate portions of some of your posts. Now get back to work saving lives!WE ALL NEED TO HELP EACHOTHER.
Important new CLRB analytic report:
https://finance.yahoo.com/news/cellectar-biosciences-pdc-delivery-platform-205418085.html
I particularly like this last part:
The peer-reviewed data in both reports was consistent in several conclusions, but one clearly stands out to benefit Cellectar: both journals provided insight, review and validation of the unique potential and varied utility of its PDC platform. With this validation comes the increased likelihood of partnership and licensing opportunities as the company continues to mature the pipeline.
It feels GOOD!!!
Like I knew it would....
High volume today, considering float
Very high volume in that context.
Churning? News coming? Flippers?
Good day so far- accumulation @ $2.00+
Next target $3.00+ In March 2017...
What if ORR is well over 30%?
Would that make you sad?
Not me!
Of course a few CR's would make me and many others very happy too.
I like to think in terms of lives more than dollars.
Perspective is our greatest asset, they say!
http://theoncologist.alphamedpress.org/content/13/suppl_2/19.full
Cs: or you can stay for the ORR ride,
WHENEVER IT STARTS.
There are a lot of MM patients like me depending on it.
$2.00 would be a good new price base
as accumulation continues. Something's happening here; what it is ain't exactly sure....
So far so good today,
CLRB's price action still bespeaks accumulation at a VERY slow rate.
Celegene? Who?
Google:
celegene acqusitions
Acquisitions (12)
UPDATE
Date Acquired Amount
Jan 26, 2017 Delinia $300M (terms undisclosed)
Jan 10, 2017 Anokion SA $45M (terms undisclosed)
Dec 2, 2016 Acetylon Pharmaceuticals Unknown
Oct 17, 2016 EngMab $600M (terms undisclosed)
Jul 14, 2015 Receptos $7.32B in Cash
Apr 27, 2015 Quanticel Pharmaceuticals $485M in Cash & Stock
Jan 26, 2012 Avila Therapeutics $350M in Cash
Jun 30, 2010 Abraxis BioScience $2.9B (terms undisclosed)
Dec 7, 2009 Gloucester Pharmaceuticals $640M in Cash & Stock
Nov 19, 2007 Pharmion $2.9B in Cash & Stock
Nov 13, 2002 Anthrogenesis Unknown
Jun 30, 2000 Signal Pharmaceuticals
I see the natives are restless here,
but I can hardly blame them!
Not expecting a company valentine on the 13th,
but who knows:
MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at the 2017 BIO CEO & Investor Conference in on Monday, February 13th at 2:00 PM ET in the Windsor Room of The Waldorf Astoria Hotel in New York City...
THINGS ARE LOOKING UP!
Around here, there will be a party soon...
http://cellectar.com/news-investors/
Seems like accumulation continues,
and price slowly drifts up lately.
GOOD SIGNS!
Today's CLRB price chart looks constructive,
...Coiled like a spring in a tight range. This happens before a sharp move in many instances.
Where will price go?
"...THE COILED SPRING
Market Type This setup is best used in:
• Bullish: strongly trending markets
• Bullish: weakly trending markets
• Range-bound markets
Characteristics This is sometimes known as a bull flag or bull pennant setup and sometimes as a symmetrical triangle pattern, depending on the shape of the coiled spring. The premise of the coiled spring is that after a strong run-up, a strong stock likes to take a breather as it consolidates the ramp-up in price. A weak stock will sell off, giving back much of its gains. But a strong stock likes to coil up in a sideways movement. As it does so, price tends to trend inside an ever tighter range the spring coils up tighter and tighter until shares are ready to climb again. When the coil finally springs open, it usually does so with a delightfully profitable burst of upward momentum.
Definition The coiled spring gets its name from the narrowing range the stock trades in over the last seven to twenty trading days as shares consolidate at or near its new high. This range can trade sideways or it can downtrend slightly, but it should not be trading at an upward angle. The key to the pattern is that the trading range, in general, is getting tighter and tighter.
Key Indicators The pattern relies on a precise definition of what is intended by coiled spring. Here are the parameters:
• In the coiled spring setup, you are looking for a weakly up trending to strongly up trending stock that has recently put in a new high. By recently we mean within the past 20 trading days. This new high must be at least a new three-month high.
• Since setting that new high, the stock has consolidated inside a coiled spring (see definition). The coiled spring can be short and tight or drawn out and choppy, but the pattern requires the coil to be tightening up (the trading range is getting smaller) as it moves further to the right.
• Note that in this setup we pay no attention to indicators. This is a pure pattern trade. All we need are the two moving averages, the 20 MA and the 50 MA, and some trend lines.
• Use the moving averages to determine that the stock is weakly or strongly up trending.
• Draw in trend lines over the top and bottom of the coiled spring. It should form a triangular shape of some kind due to the narrowing trading range of the coil but should not be angled upward.
• It is essential that the coiled spring last at least seven but no more than 20 trading days. It is also essential that no part of the coil extend to or beyond the 50 MA. It can pass over the 20 MA, but not the 50 MA.
• Buy signal: The coiled spring itself puts the stock on the shortlist. A break of the trend line drawn over the tops of this coil marks the buy signal. A close below the lower trend line negates the coiled spring, remove it then from the shortlist..."
Today's News headline:
MADISON, Wis., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the advance online publication of an article in Nature Reviews Clinical Oncology. In addition, the company anticipates an oral presentation on its drug delivery platform at the Academic Surgical Congress on February 8, 2017, at the Encore Hotel, Las Vegas. Each publication increases our understanding regarding the unique tumor targeting ability of the company’s phospholipid drug conjugates (PDCs) with fluorescent payloads....
Life is risky,
But there will be no more stock splits if progress is fast enough in clinical trials.
Most famous stocks were risky before they took off. There was a receptionist at Microsoft who was paid mainly with stock options in the 1990's who retired very early and very 7 figure rich. She took a risk.
So am I with CLRB. No predictions here, just risk. Stay informed.
ash111: yes, those are the risks,
so you should not buy shares here or, in the alternative, be a flipper.
But if CLR131 and 125 are found to be effective, then owning CLRB in advance of that clinical test finding will make a risk taker RICH and get them into a new US Mail zip code.
FEAR OR GREED? PLACE YER BETS!
Last trade today looks to be $1.50
or lower. News of Biotech conference and the latest patents are not going to establish a new base and a new uptrend.
It will take Clinical trial success and corresponding income growth potential to get us to $3 and $7 again.
It is all about earnings and verified potential earning. Share price follows those factors as we all know.
GOOD luck to all longs!
Good analysis: base, uptrend and longer term,
...Or not! Honest and factual.
It is like measuring rainfall or snow with wind direction factored in- only its money!
Thanks, Clay!
$1.60 would be good new base,
...But the day and week are young!
It takes discipline to invest successfully:
Love the computer programs,
"HAL, WHAT ARE YOU DOING, HAL?"
No, ""Dave, what are you doing Dave (selling?)?
Flippers are more likely,
But "who nose"?
If nothing else, we just got a taste of what real news will be like.
Even if CLRB goes back to $1.25, I am holding for a Ten Bagger before executing my exit plan.
HOD: $1.95 on this:
"...The granted patent covers the use of CLR 131 for the potential treatment of a broad range of malignant solid tumors, which include adrenal, lung, ovarian or cervical, prostate, liver, breast and colon, as well as melanoma or subcutaneous cancers. "